Abstract:Background: Atherosclerosis is a chronic inflammatory disorder whose development is inversely correlated with high-density lipoprotein concentration. Current therapies involve pharmaceuticals that significantly elevate plasma high-density lipoprotein cholesterol concentrations. Our studies were conducted to investigate the effects of low-dose lipid-free apolipoprotein A-I (apoA-I) on chronic inflammation. The aims of these studies were to determine how subcutaneously injected lipid-free apoA-I reduces accumulation of lipid and immune cells within the aortic root of hypercholesterolemic mice without sustained elevations in plasma high-density lipoprotein cholesterol concentrations. Methods and results: Ldlr-/- and Ldlr-/- apoA-I-/- mice were fed a Western diet for a total of 12 weeks. After 6 weeks, a subset of mice from each group received subcutaneous injections of 200 μg of lipid-free human apoA-I 3 times a week, while the other subset received 200 μg of albumin, as a control. Mice treated with lipid-free apoA-I showed a decrease in cholesterol deposition and immune cell retention in the aortic root compared with albumin-treated mice, regardless of genotype. This reduction in atherosclerosis appeared to be directly related to a decrease in the number of CD131 expressing cells and the esterified cholesterol to total cholesterol content in several immune cell compartments. In addition, apoA-I treatment altered microdomain cholesterol composition that shifted CD131, the common β subunit of the interleukin 3 receptor, from lipid raft to nonraft fractions of the plasma membrane. Conclusions: ApoA-I treatment reduced lipid and immune cell accumulation within the aortic root by systemically reducing microdomain cholesterol content in immune cells. These data suggest that lipid-free apoA-I mediates beneficial effects through attenuation of immune cell lipid raft cholesterol content, which affects numerous types of signal transduction pathways that rely on microdomain integrity for assembly and activation.

Apolipoprotein A-II alters the proteome of human lipoproteins and enhances cholesterol efflux from ABCA1

The influence of plasma apolipoprotein A-II concentrations on HDL subclass distribution

ApoA-II Maintains HDL Levels in Part by Inhibition of Hepatic Lipase. Studies in Apoa-Ii and Hepatic Lipase Double Knockout Mice.

Lipid exchange of apolipoprotein A‐I amyloidogenic variants in reconstituted high‐density lipoprotein with artificial membranes

Effect of apoA-I Mutations in the Capacity of Reconstituted HDL to Promote ABCG1-Mediated Cholesterol Efflux

Abstract 53: An Abundant Dysfunctional Apolipoprotein A1 in Human Atheroma

Human apolipoprotein A-II protects against diet-induced atherosclerosis in transgenic rabbits

ApoA-I Mimetic Peptides Promote Pre-Β HDL Formation in Vivo Causing Remodeling of HDL and Triglyceride Accumulation at Higher Dose

Apolipoprotein A1 and high-density lipoprotein limit low-density lipoprotein transcytosis by binding scavenger receptor B1

Apolipoprotein A1 and high-density lipoprotein limit low-density lipoprotein transcytosis by binding SR-B1

Function of Different Proportions of Apolipoprotein A-I Cysteine Mutants and Apolipoprotein A-V on Recombinant High-Density Lipoproteins in Vitro.

Phospholipase A2 group IIA correlates with circulating high-density lipoprotein cholesterol and modulates cholesterol efflux possibly through regulation of PPAR-γ/LXR-α/ABCA1 in macrophages

Human apolipoprotein A-II reduces atherosclerosis in knock-in rabbits

An abundant dysfunctional apolipoprotein A1 in human atheroma

HDL Modification by Secretory Phospholipase A2 Promotes Scavenger Receptor Class B Type I Interaction and Accelerates HDL Catabolism

Expression of Human Apoaii in Transgenic Rabbits Leads to Dyslipidemia A New Model for Combined Hyperlipidemia

Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL

Relationship Between Apolipoproteins and the Alteration of HDL Subclasses in Hyperlipidemic Subjects.

Lipid-Free Apolipoprotein A-I Reduces Progression of Atherosclerosis by Mobilizing Microdomain Cholesterol and Attenuating the Number of CD131 Expressing Cells: Monitoring Cholesterol Homeostasis Using the Cellular Ester to Total Cholesterol Ratio

HDL Particle Size is a Critical Determinant of ABCA1-Mediated Macrophage Cellular Cholesterol Export

Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux